Zhaoke Ophthalmology (HKSE:06622) ROCE % : -13.55% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zhaoke Ophthalmology's annualized ROCE % for the quarter that ended in Dec. 2023 was -13.55%.

Zhaoke Ophthalmology ROCE % Historical Data

The historical data trend for Zhaoke Ophthalmology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology ROCE % Chart

Zhaoke Ophthalmology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-32.53

-95.40

-116.53

-15.74

-16.70

Zhaoke Ophthalmology Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-10.94	-12.45	-19.55	-19.62	-13.55

Zhaoke Ophthalmology ROCE % Calculation

Zhaoke Ophthalmology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-411.881	/	( ( (2870.653 - 217.246)	+	(2647.315 - 368.003) )	/ 2 )
	=	-411.881	/	( (2653.407	+	2279.312)	/ 2 )
	=	-411.881	/	2466.3595
	=	-16.70 %

Zhaoke Ophthalmology's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-321.496	/	( ( (2775.322 - 307.77)	+	(2647.315 - 368.003) )	/ 2 )
	=	-321.496	/	( ( 2467.552	+	2279.312 )	/ 2 )
	=	-321.496	/	2373.432
	=	-13.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Zhaoke Ophthalmology (HKSE:06622) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zhaoke Ophthalmology ROCE % Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology (HKSE:06622) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN

Website

https://www.zkoph.com

Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.

Executives

Mak Siu Hang Viola	2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd	2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd	2101 Beneficial owner
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Fidelity China Special Situations Plc	2101 Beneficial owner
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Vms Holdings Limited	2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited	2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p.	2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p.	2201 Interest of corporation controlled by you

Zhaoke Ophthalmology (HKSE:06622) Headlines

No Headlines